ArticleFertility and sterility2025
Association of polycystic ovary syndrome with endothelial health, cardiovascular risk, and cellular aging.
Article in Fertility and sterility, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Divergent Immune and Endothelial Responses to Insulin Resistance in Women with Polycystic Ovary Syndrome.International journal of molecular sciences · 2026Article
- Urinary Albumin-to-Creatinine Ratio Across Phenotypes of Polycystic Ovary Syndrome: A Phenotype-Based Evaluation.Metabolites · 2026Article
- Bu-Shen-Tian-Jing Formula alleviates oxidative-inflammatory stress in granulosa cells of polycystic ovary syndrome through AGEs-RAGE/NOX4/NF-κB pathway.Chinese medicine · 2026Article
- Molecular signatures of hypertension in polycystic ovary syndrome: Endothelin-1 and CYP11A1 as biomarkers of vascular and metabolic dysfunction.Molecular biology reports · 2026Article
- ApoB and LDL partially explain the association between family history of diabetes and lower clinical pregnancy in women who conceived with PCOS.Frontiers in nutrition · 2026Article
- Living with PCOS: A Narrative of its Biology, Diagnosis, and Evolving Treatment.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Drug-induced polycystic ovary syndrome: a real-world pharmacovigilance study based on the FAERS database.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo study measures of endothelial health, cardiovascular risk, and cellular aging between patients with polycystic ovary syndrome (PCOS) and a reproductive age normative cohort.
designCross-sectional study. SUBJECTS: Community-based patients with PCOS and a normative ovarian aging cohort as controls, aged ≤45 years at the time of evaluation. EXPOSURE: Noninvasive measure of endothelial health measured by the EndoPAT reactive hyperemia index.
main outcome measuresReactive hyperemia index as measure of endothelial health. The secondary outcomes included Framingham score, telomere length, and mitochondrial deoxyribonucleic acid copy number from leukocyte cells.
resultsOur cohort included 63 participants with PCOS and 130 non-PCOS participants. The mean age was significantly lower in the PCOS cohort (33.1; standard deviation, 4.7 years) than in the non-PCOS cohort (40.8; standard deviation, 2.9 years). In multivariable-adjusted models, we found that PCOS was significantly associated with endothelial dysfunction as both categorical (odds ratio for PCOS, 0.31; 95% confidence interval [CI], 0.10-0.97) and continuous (PCOS coefficient, -0.37; 95% CI, -0.69 to -0.05) outcomes. For secondary outcomes, PCOS status was not significantly associated with mitochondrial deoxyribonucleic acid (PCOS coefficient, -48.1; 95% CI, -175.0 to 78.9), telomere length (PCOS coefficient, 0.05; 95% CI, -0.05 to 0.15), Framingham score (PCOS coefficient, 0.002; 95% CI, -0.01 to 0.02), or metabolic syndrome (odds ratio for PCOS, 1.29; 95% CI, 0.31-5.44).
conclusionOur findings suggest that patients with PCOS have impaired endothelial function compared with non-PCOS patients, although measures of cellular aging and cardiovascular risk as measured by the Framingham score did not differ between the cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.